Guanine nucleotide exchange factor H1 can be a new biomarker of melanoma.

Abstract

Guanine nucleotide exchange factor H1 (GEF-H1), which couples microtubule dynamics to RhoA activation, is a microtubule-regulated exchange factor. Studies have shown that GEF-H1 can be involved in various cancer pathways; however, the clinical significance of GEF-H1 expression and functions in melanoma has not been established. In this study, we investigated the relationship between clinical outcomes and GEF-H1 functions in melanoma. A total of 60 cases of different grades of melanoma samples were used to detect the expression of GEF-H1. Results showed that both messenger RNA and protein levels of GEF-H1 were significantly higher in high-grade melanomas. Furthermore, patients with high GEF-H1 expression had a shorter overall survival (22 months) than patients with low level of GEF-H1 expression (33.38 months). We also found that GEF-H1 can promote the proliferation and metastasis of melanoma cells. In summary, these results suggested that GEF-H1 may be a valuable biomarker for assessing the degree and prognosis of melanoma following surgery.

• Authors: Jie Shi, Bingyu Guo, Yu Zhang, Qiang Hui, Peng Chang, Kai Tao
• Journal: Biologics : targets & therapy (Biologics) Vol. 10 Pg. 89-98 ( 2016) ISSN: 1177-5475 [Print] New Zealand
• PMID: 27462139 (Publication Type: Journal Article)